OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
WATERTOWN, Mass., Sept. 20, 2016 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its new President and Chief Executive Officer, Nancy Lurker. The awards were approved by the Compensation Committee and ratified by the full Board of Directors on September 14, 2016, as an inducement material to Ms. Lurker’s entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The awards are subject to shareholder approval in accordance with ASX Listing Rules.
The inducement awards consist of a non-qualified stock option to purchase 850,000 shares of common stock and performance stock units (“PSUs”) entitling Ms. Lurker to receive up to 500,000 shares of common stock based on achievement of specified target total shareholder returns. The stock option has an exercise price of $3.63 per share (the closing price per share of the company’s common stock reported by NASDAQ on the date of grant, September 15, 2016) and a ten-year term, and will vest as to 25% of the award on each of the first, second, third and fourth anniversaries of grant, subject to the terms of grant. The PSUs will vest on the third anniversary of grant, subject to the terms of grant.
About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the United States and three E.U. countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact: Michael Polyviou 212-850-6020 [email protected] Douglas Sherk 415-652-9100 [email protected]
